Oncology patient recruitment
Having supported 50+ oncology studies, we know how difficult the oncology space can be.
For years, sponsors have been experiencing costly, inefficient, and increasingly difficult-to-scale recruitment. While you continue to pursue the next breakthrough cancer treatment, we’re actively piloting our potential breakthrough oncology recruitment model, built on 20 years’ experience and the patient voices of thousands of oncology patients.
The oncology trial landscape
24,300+
Oncology trials actively recruiting
14,200+
study sites seeking patients
7,700+
Clinical trial sponsors
In a market with 24,300+ clinical trials targeting a limited pool of patients, compounded by the previously immovable barriers to recruiting patients for oncology clinical trials, now is the time to speak to Clariness about your study.
More patients, same problems
Cancer diagnoses are projected to grow by 75% to 35M annual cases in 2050, yet only <3% of the patient population have ever joined a trial.
- 4–12-week diagnosis-to-treatment windows make timing everything
- Physicians refer just 0.2% of their patients into clinical trials
- >20% of sites fail to enroll a single oncology patient
It’s no surprise why oncology trials fail to reach their minimum enrollment targets 2-4x more often than other therapeutic areas. Luckily, Clariness has 20 years’ experience closing the gap between your targets and eligible patients.
Proven results in oncology recruitment
50+
Global oncology studies supported
20+
Years of therapeutic expertise
10+
Oncology indications supported
Breast cancer
Delivered recruitment for 10+ breast cancer trials, supporting enrollment across diverse patient populations.
Leukemia
Supporting leukemia clinical trials with recruitment strategies tailored to complex study criteria.
Lung cancer
30+ lung cancer clinical trials supported through precision recruitment for complex oncology protocols.
Spotlight: Clariness campaign pushed >300,000 patients to ClinLife®
Project overview:
- Online patient recruitment for a Phase III anaplastic astrocytoma study (rare)
- 6 countries (AU, DE, ES, PL, RU, US) with 53 sites, over 51 weeks
- Our approach included online awareness campaigns, a pre-qualification process, direct scheduling of screening visits, and site helpdesks to optimize patient contact
Our results:
- 300,000+ patients driven to the study, hosted on our ClinLife® platform
- 40 patients referred for a rare brain cancer with a prevalence of <0.001%
Clariness can help you reach the right patients, at the right point of time
Between diagnosis and treatment decisions, patients have a window of just 4-12 weeks to explore all care options, including clinical trials.
That’s why we developed our oncology service, which introduces Clariness Oncology Companions into the recruitment journey.
Here’s how it works:
- Early patient engagement pre- and between diagnosis and treatment decisions
- Our dedicated oncology companions engage and guide patients, their support network, tumor board and HCPs to facilitate informed treatment decisions
- This engagement by a trained oncologist ensures your trial is well considered as a treatment option by the patient’s treating physician
Boost physician referrals for your oncology trials with our oncology companions.
What do our patients say?
Oncology FAQs
What are the biggest recruitment challenges in oncology clinical trials?
Oncology clinical trials often aim to recruit highly specific patient populations defined by cancer type, stage, line of therapy, biomarkers, and prior treatments. Rapidly evolving standards of care and competing clinical trials further reduce the pool of eligible participants. Clariness addresses these challenges through protocol-specific recruitment strategies, hybrid recruitment models, and close collaboration with study sites to improve referral quality.
Why are treating physicians important in oncology patient recruitment?
Many patients first learn about clinical trial opportunities through their treating physicians, making physician trust and engagement essential to oncology recruitment. Clariness works alongside study sites and referral networks to support physician engagement while complementing site-based recruitment with targeted patient outreach where appropriate.
How many oncology indications does Clariness support?
Clariness supports a wide range of oncology indications including breast cancer, leukemia, lung cancer, renal cell carcinoma, anaplastic astrocytoma, lymphoma, Glioblastoma, ovarian cancer, metastatic pancreatic adenocarcinoma, melanoma, multiple myeloma, and many others.
Why is timing critical in oncology patient recruitment?
For many patients, the period between cancer diagnosis and treatment decisions is the only opportunity to consider a clinical trial. Once treatment begins or the disease progresses, patients may no longer be eligible. Clariness helps sponsors engage patients early through targeted recruitment strategies that maximize this critical recruitment window.
How does Clariness recruit patients for biomarker-driven oncology clinical trials?
Many precision oncology studies require patients with specific genetic mutations or biomarker profiles, making recruitment increasingly complex. Clariness incorporates protocol-specific biomarkers and line-of-therapy requirements into its recruitment and pre-screening strategies to help identify eligible participants while reducing unnecessary site burden.
